Biopharmaceutical News and Research

RSS

DelSite's assests acquired by Nanotherapeutics

Nanotherapeutics, Inc., a privately held specialty biopharmaceutical company, announced today that it had acquired certain assets from DelSite (formerly Carrington Laboratories, Inc.) out of Chapter 7 bankruptcy proceedings in the U.S. Bankruptcy Court for the Northern District of Texas, Dallas Division.

3 Oct 2009

Provectus Pharmaceuticals commences Phase 1 study of PV-10 for liver cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 1 study of PV-10 for liver cancer. The study will enroll up to six subjects with cancer metastatic to the liver or with recurrent liver cancer. PV-10 is the company’s lead oncology drug candidate that is also currently undergoing Phase 2 study for metastatic melanoma.

1 Oct 2009

Raptor and TorreyPines Therapeutics announce merger completion

Raptor Pharmaceuticals Corp. ("Raptor") (OTC Bulletin Board: RPTP) and TorreyPines Therapeutics, Inc. ("TorreyPines") (Nasdaq: TPTX) announced today the completion of their merger.

1 Oct 2009

Can-Fite BioPharma commences preparatory work for a Phase III trial with CF101 to treat Psoriasis

Can-Fite BioPharma, a biotechnology company traded on the Tel Aviv Stock Exchange, an Israeli Biopharmaceutical company, announced today the initiation of preparatory work for a Phase III trial with CF101 in Psoriasis. This is based on the successful conclusion of a Phase II dose-response clinical study with CF101 to treat patients with moderate to severe Psoriasis; the study successfully met its primary objective of efficacy and safety

1 Oct 2009

CBR Pharma reports on M&A in the biopharmaceutical industry

The history of the pharmaceutical industry is closely linked to the business practices of the combination and purchase of corporations. From the creation of the combined entity of Warner-Lambert in 1955, to the purchase of Warner-Lambert by Pfizer in 2000, to the recent acquisition of Wyeth, pharmaceutical and biotech companies have expanded their pipelines, portfolios, and sales forces through mergers and acquisitions (M&A).

30 Sep 2009

Æterna Zentaris announces results of its cetrorelix pamoate clinical development program TQT trial

Æterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that the 043 Thorough QT (TQT) trial, which is part of the cetrorelix pamoate clinical development program in benign prostatic hyperplasia (BPH), met its primary endpoint.

30 Sep 2009

NIH awards Novelos and MGH $1M grant for the study of compounds for radiation-induced lung injury

Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the Massachusetts General Hospital (MGH), in collaboration with Novelos, was awarded a $950,371 competitive grant by the National Institutes of Health (NIH) to study two Novelos compounds – NOV-002 and NOV-205 – for the mitigation and treatment of radiation-induced pulmonary injury.

29 Sep 2009

Renewed GMP certification for China Biologic Products' Qianfeng subsidiary

China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("China Biologic," or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), today announced that on September 2, 2009, the PRC's State Food and Drug Administration (the "SFDA") renewed SFDA certification of compliance with Good Manufacturing Practices ("GMP") for the production facility of Qianfeng Biological Products Co., Ltd. ("Qianfeng"), China Biologic's indirectly owned subsidiary.

29 Sep 2009

Synta commences Phase 1/2 clinical study of novel Hsp90 inhibitor in hematologic malignancies

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it has initiated a Phase 1/2 clinical study of its novel heat shock protein 90 (Hsp90) inhibitor, STA-9090 in hematologic malignancies with a once-a-week dosing schedule.

29 Sep 2009

Oculus launches Microcyn Skin & Wound HydroGel OTC

Oculus Innovative Sciences, Inc., a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to treat chronic and acute wounds, today launched Microcyn Skin & Wound HydroGel for both the U.S. professional and over-the-counter markets. The Microcyn HydroGel received FDA 510(k) marketing clearance in May of this year.

29 Sep 2009

Laureate Pharma sign development and manufacturing agreement with ZZ Biotech

Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it has entered into a development and manufacturing agreement with ZZ Biotech, LLC. According to the agreement, Laureate will produce Activated Protein C variant under cGMP conditions. Terms of the manufacturing agreement were not disclosed.

28 Sep 2009

Auxilium Pharmaceuticals declares pricing of common stock shares

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced the pricing of a public offering of 3 million shares of its common stock.

26 Sep 2009

RXi Pharmaceuticals acquires self-delivering rxRNA technology platform from Advirna

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that it has recently acquired direct ownership of technology for which it had previously exercised its option to exclusively license from Advirna LLC.

25 Sep 2009

Qrxpharma forms an alliance with Liaoning Nuokang Medicines to commercialise its venomics assets

QRxPharma Limited,announced today a strategic alliance with Liaoning Nuokang Medicines Co. Ltd. ("Nuokang"), a Chinese biopharmaceutical company based in Shenyang, China, to develop and commercialise QRxPharma's venomics assets for the Chinese market.

25 Sep 2009

Partial success reported in the Phase 3 trial of HIV/AIDS vaccine

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), was pleased to hear the announcement today of partial success in the recently completed Phase 3 trial in Thailand of a candidate HIV/AIDS vaccine owned by Sanofi-Aventis and Global Solutions for Infectious Diseases.

25 Sep 2009

Octapharma AG submits Biological License Application for its octagam(R) 10% to FDA

Octapharma AG recently submitted its Biological License Application for octagam(R) 10% (human normal intravenous immunoglobulin, liquid) to the U.S. Food and Drug Administration (FDA) with the goal of expanding the biopharmaceutical company's U.S. immune globulin therapy portfolio by early 2010. The application was submitted for the treatment of Idiopathic Thrombocytopenic Purpura (ITP), a blood-clotting disorder that can result in excessive bruising and bleeding.

24 Sep 2009

ThromboGenics completes enrollment for MIVI-TRUST clinical trial

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that it has completed the enrolment of the US Phase III trial evaluating microplasmin for the non-surgical treatment of eye disease.

24 Sep 2009

Court rules in favor of Eli Lilly for Evista's method-of-use patents

The U.S. District Court for the Southern District of Indiana today upheld Eli Lilly and Company's (NYSE: LLY) method-of-use patents on Evista(R) (raloxifene HCl tablets). In the case of Eli Lilly and Company v. Teva Pharmaceuticals Industries Ltd., the court ruled in favor of Lilly on all accounts for these method-of-use patents, including the patent doctrines of obviousness, enablement, and inequitable conduct.

24 Sep 2009

New Fluorescence Molecular Tomography imaging systems from VisEn Medical

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced the launch and availability of a new Fluorescence Molecular Tomography (FMT) imaging system -- the FMT 1500, and an advanced version of its FMT 2500, the FMT 2500 LX.

23 Sep 2009